These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38676875)

  • 1. Cost-Effectiveness Analysis of Fluocinolone Acetonide Intravitreal (FAI) Implant for Chronic Noninfectious Uveitis Affecting the Posterior Segment of the Eye (NIU-PS) in China.
    Mao X; Dai Z; Yang J; Wu Y; Xie F; Lu Y; Yu J; Chang F; Lu Y
    Ophthalmol Ther; 2024 Jun; 13(6):1757-1772. PubMed ID: 38676875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Pouwels XGLV; Petersohn S; Carrera VH; Denniston AK; Chalker A; Raatz H; Armstrong N; Shah D; Witlox W; Worthy G; Noake C; Riemsma R; Kleijnen J; Joore MA
    Pharmacoeconomics; 2020 May; 38(5):431-441. PubMed ID: 31701471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 0.2-μg/day Fluocinolone Acetonide Intravitreal Implant in Chronic Noninfectious Posterior Uveitis: A 3-year Randomized Trial in India.
    Biswas J; Tyagi M; Agarwal M;
    Ophthalmol Sci; 2024; 4(1):100403. PubMed ID: 38027419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single Institution Experience of Intravitreal 0.18-mg Fluocinolone Acetonide Implant for Noninfectious Uveitis.
    Reddy AK; Pecen PE; Patnaik JL; Palestine AG
    Ophthalmol Retina; 2023 Jan; 7(1):67-71. PubMed ID: 35820567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-infectious uveitis affecting the posterior segment treated with fluocinolone acetonide intravitreal implant: 3-year fellow eye analysis.
    Pavesio C; Heinz C
    Eye (Lond); 2022 Jun; 36(6):1231-1237. PubMed ID: 34117380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies.
    Pochopien M; Beiderbeck A; McEwan P; Zur R; Toumi M; Aballéa S
    BMC Health Serv Res; 2019 Jan; 19(1):22. PubMed ID: 30626376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults.
    Squires H; Poku E; Bermejo I; Cooper K; Stevens J; Hamilton J; Wong R; Denniston A; Pearce I; Quhill F
    Health Technol Assess; 2017 Nov; 21(68):1-170. PubMed ID: 29183563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of fluocinolone acetonide implant versus systemic therapy for noninfectious intermediate, posterior, and panuveitis.
    ; Sugar EA; Holbrook JT; Kempen JH; Burke AE; Drye LT; Thorne JE; Louis TA; Jabs DA; Altaweel MM; Frick KD
    Ophthalmology; 2014 Oct; 121(10):1855-62. PubMed ID: 24908205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluocinolone acetonide 0.2 µg/day intravitreal implant in non-infectious uveitis affecting the posterior segment: EU expert user panel consensus-based clinical recommendations.
    Pleyer U; Pavesio C; Miserocchi E; Heinz C; Devonport H; Llorenç V; Burke T; Nogueira V; Kodjikian L; Bodaghi B
    J Ophthalmic Inflamm Infect; 2024 May; 14(1):22. PubMed ID: 38814386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a Fluocinolone Acetonide Insert on Recurrence Rates in Noninfectious Intermediate, Posterior, or Panuveitis: Three-Year Results.
    Jaffe GJ; Pavesio CE;
    Ophthalmology; 2020 Oct; 127(10):1395-1404. PubMed ID: 32624244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China.
    Liu Q; Luo X; Peng L; Yi L; Wan X; Zeng X; Tan C
    BMJ Open; 2020 Nov; 10(11):e040691. PubMed ID: 33243806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
    Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
    Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Injectable Fluocinolone Acetonide Long-Acting Implant for Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Two-Year Results.
    Jaffe GJ; Lin P; Keenan RT; Ashton P; Skalak C; Stinnett SS
    Ophthalmology; 2016 Sep; 123(9):1940-8. PubMed ID: 27421623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventing relapse in non-infectious uveitis affecting the posterior segment of the eye - evaluating the 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN
    Bodaghi B; Nguyen QD; Jaffe G; Khoramnia R; Pavesio C
    J Ophthalmic Inflamm Infect; 2020 Nov; 10(1):32. PubMed ID: 33251553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluocinolone acetonide 0.19-mg implant for the treatment of noninfectious uveitis with involvement of the posterior segment: a real-world study.
    Buhl L; Thurau S; Kern C
    Graefes Arch Clin Exp Ophthalmol; 2023 Apr; 261(4):1101-1108. PubMed ID: 36399176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
    Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
    Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal Fluocinolone 0.19mg Implant in the Management of Chronic Non-Infectious Uveitis: 12-Month Outcomes from a Single Tertiary Centre.
    Pockar S; Leal I; Chhabra R; Jones NP; Steeples LR
    Ocul Immunol Inflamm; 2023 Oct; 31(8):1572-1578. PubMed ID: 34124978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective.
    Zhang J; Xia Z; Guo W; Ren X; Liu F; Ratnaparkhi G; Pagada A; Subramanian S; Hu M; Chen W
    Dermatol Ther (Heidelb); 2023 Nov; 13(11):2681-2696. PubMed ID: 37741954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China.
    Yao Y; Zhang R; An T; Zhao X; Zhang J
    ESC Heart Fail; 2020 Dec; 7(6):3582-3592. PubMed ID: 33107212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.